Urinary Tract Obstruction disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: URN010 MIFTS: 54	Urinary Tract Obstruction Categories: Nephrological diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Urinary Tract Obstruction

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction ¹¹ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Obstructive Uropathy ¹¹ ⁵³ ¹⁴

Urinary Obstruction ¹¹

Urologic Diseases ⁷¹

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the genitourinary system

Renal tubulo-interstitial diseases

Obstructive and reflux uropathy

Obstructive and reflux uropathy, unspecified

External Ids:

Disease Ontology ¹¹ DOID:5200

ICD9CM ³⁴ 599.6

NCIt ⁴⁹ C79805

SNOMED-CT ⁶⁸ 7163005

ICD10 ³¹ N13.9

EFO ¹⁶ EFO_0009571

UMLS ⁷¹ C0042075 C0178879

Sources

Summaries for Urinary Tract Obstruction

MalaCards based summary: Urinary Tract Obstruction, also known as obstructive uropathy, is related to congenital anomalies of kidney and urinary tract 2 and obstructive nephropathy, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is BNC2 (Basonuclin 2), and among its related pathways/superpathways are Epithelial to mesenchymal transition in colorectal cancer and Cell adhesion_ECM remodeling. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: ⁷⁵ Urinary tract obstruction is a urologic disease consisting of a decrease in the free passage of urine... more...

Sources

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)

#	Related Disease	Score	Top Affiliating Genes
1	congenital anomalies of kidney and urinary tract 2	32.3	UMOD REN LCN2 HAVCR1 AQP2
2	obstructive nephropathy	31.8	SMAD3 SMAD2 REN LCN2 HAVCR1 FN1
3	oligohydramnios	31.6	REN CRP ALB
4	urethral stricture	31.5	KLK3 CRP CCN2
5	hydronephrosis	31.3	REN NAGLU MIR192 LCN2 KLK3 HAVCR1
6	neurogenic bladder	31.1	KLK3 CRP ALB
7	urinary tract infection	31.1	UMOD REN LCN2 KLK3 HAVCR1 CRP
8	aortic aneurysm	31.0	SMAD3 SMAD2 REN CRP ALB
9	chronic pyelonephritis	31.0	UMOD REN CRP B2M ALB
10	cystitis	31.0	UMOD HBEGF CRP CDH1
11	urolithiasis	30.9	UMOD CDH1 ALB
12	aortic aneurysm, familial abdominal, 1	30.8	REN MIR199A1 LCN2 FN1 CRP ALB
13	acute kidney failure	30.8	UMOD REN LCN2 HAVCR1 B2M ALB
14	chronic kidney disease	30.8	UMOD REN LCN2 CRP CCN2 B2M
15	cakut	30.8	UMOD REN GDNF AQP2
16	renal hypertension	30.8	REN FN1 CRP ALB
17	actinomycosis	30.8	CRP ALB
18	ureterolithiasis	30.8	KLK3 CRP ALB
19	pyelonephritis	30.8	UMOD NAGLU LCN2 CRP AQP2 ALB
20	urogenital tuberculosis	30.8	KLK3 CRP ALB
21	pericardial effusion	30.7	REN CRP ALB
22	preterm premature rupture of the membranes	30.7	MIR199A1 FN1 CRP
23	compartment syndrome	30.7	LCN2 CRP ALB
24	anuria	30.7	REN LCN2 HAVCR1 CRP ALB
25	uremia	30.7	REN CRP B2M ALB
26	appendicitis	30.7	LCN2 CRP ALB
27	bowel dysfunction	30.7	LCN2 CRP ALB
28	vesicoureteral reflux	30.6	UMOD REN NAGLU LCN2 HAVCR1 GDNF
29	kidney papillary necrosis	30.6	UMOD REN HAVCR1 AQP2 ALB
30	peritonitis	30.6	LCN2 CRP B2M ALB
31	pelvic inflammatory disease	30.6	LCN2 CRP CDH1
32	hyperuricemia	30.6	UMOD REN LCN2 HAVCR1 CRP ALB
33	respiratory failure	30.6	REN MIR199A1 CRP ALB
34	urinary system disease	30.6	UMOD REN NAGLU MIR199A1 MIR192 KLK3
35	wilms tumor 1	30.5	REN MIR199A1 CDH1 CCN2 ALB
36	prostatic hypertrophy	30.5	KLK3 CRP ALB
37	bacteriuria	30.5	UMOD CRP ALB
38	lymphocele	30.5	KLK3 ALB
39	urethritis	30.5	KLK3 CRP ALB
40	hypertensive retinopathy	30.5	REN CRP ALB
41	deficiency anemia	30.5	REN FN1 CRP B2M ALB
42	necrotizing fasciitis	30.5	FN1 CRP ALB
43	cardiac tamponade	30.5	REN CRP ALB
44	renal tubular acidosis	30.5	REN B2M AQP2
45	diabetes mellitus, ketosis-prone	30.5	REN CRP ALB
46	clear cell adenocarcinoma	30.5	SMAD3 SMAD2 KLK3
47	kidney disease	30.5	UMOD SMAD3 REN NAGLU MIR199A1 LCN2
48	cystic kidney disease	30.5	UMOD REN MIR199A1 LCN2 HAVCR1 CRP
49	inguinal hernia	30.5	NAGLU KLK3 CRP ALB
50	renal tuberculosis	30.4	REN CRP B2M ALB

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 20)

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:

Sources

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:

dysuria; polyuria; urgency of micturition; other and unspecified genitourinary symptoms; renal colic; pain in urethra; uti symptoms; urethral burning on micturition; loin pain; ureteral pain; flank tenderness; difficulty passing urine; urinary tenesmus; burning urination; bladder discomfort; renal pain; urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.25	ALB AQP2 B2M CCN2 CDH1 CRP
2	growth/size/body region	MP:0005378	10.24	AQP2 B2M BNC2 CCN2 CDH1 FN1
3	cardiovascular system	MP:0005385	10.13	ALB B2M CCN2 CDH1 CRP FN1
4	renal/urinary system	MP:0005367	10.11	ALB AQP2 GDNF LCN2 MIR192 NAGLU
5	liver/biliary system	MP:0005370	10.03	ALB B2M CCN2 FN1 LCN2 NAGLU
6	immune system	MP:0005387	9.97	ALB B2M CDH1 CRP FN1 GDNF
7	digestive/alimentary	MP:0005381	9.92	ALB B2M BNC2 CCN2 CDH1 GDNF
8	mortality/aging	MP:0010768	9.86	ALB AQP2 B2M BNC2 CCN2 CDH1
9	integument	MP:0010771	9.28	AQP2 B2M CCN2 CDH1 FN1 HBEGF

Sources

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetaminophen

Approved

Phase 4

103-90-2

1983

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Sennosides

Experimental

Phase 4

517-43-1

Uric acid

Investigational

Phase 4

69-93-2

1175

Polyethylene glycol 3350

Phase 4

Senna

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Vitamins

Phase 4

Trace Elements

Phase 4

Hematinics

Phase 4

Micronutrients

Phase 4

Anesthetics, Local

Phase 4

Narcotics

Phase 4

Analgesics, Opioid

Phase 4

Tamsulosin

Approved, Investigational

Phase 3

106133-20-4

129211

Mirabegron

Approved

Phase 3

223673-61-8

18319735 9865528

Pregabalin

Approved, Investigational

Phase 3

148553-50-8

5486971

Lomefloxacin

Approved, Investigational

Phase 3

98079-51-7

3948

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Propiverine

Approved, Investigational

Phase 3

60569-19-9

4942

Furosemide

Approved, Vet_approved

Phase 3

54-31-9

3440

Analgesics

Phase 3

Adrenergic beta-Agonists

Phase 3

Adrenergic beta-3 Receptor Agonists

Phase 3

Adrenergic Agonists

Phase 3

Adrenergic Agents

Phase 3

Solifenacin Succinate

Phase 3

242478-38-2

216457

Muscarinic Antagonists

Phase 3

Cholinergic Antagonists

Phase 3

Cholinergic Agents

Phase 3

Anti-Anxiety Agents

Phase 3

calcium channel blockers

Phase 3

Anti-Infective Agents

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Parasympatholytics

Phase 3

Sodium Potassium Chloride Symporter Inhibitors

Phase 3

diuretics

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 1, Phase 2

33069-62-4

36314

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Neurotransmitter Agents

Phase 2

Interventional clinical trials:

(show top 50) (show all 162)

#	Name	Status	NCT ID	Phase	Drugs
1	Optimizing Pain Control in Transurethral Resection of the Prostate	Unknown status	NCT04102566	Phase 4	Ibuprofen 600 mg
2	Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty	Unknown status	NCT02444013	Phase 4	Folic acid;Placebo
3	Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures	Completed	NCT02805504	Phase 4	Exparel;Marcaine
4	A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures	Recruiting	NCT04826484	Phase 4	Exparel 133 miligrams per 10 milliliter injection;Bupivacaine Hydrochloride
5	Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery	Withdrawn	NCT03591289	Phase 4	NMB with rocuronium bromide
6	Uroflowmetry Parameter (Delta Q Value) as a Noninvasive Tool to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction	Completed	NCT05359484	Phase 2, Phase 3
7	A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms	Completed	NCT01908829	Phase 3	mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
8	Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot	Completed	NCT03927781	Phase 3	Pregabalin 300mg
9	A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder	Completed	NCT02045862	Phase 3	Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
10	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder	Completed	NCT01972841	Phase 3	Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
11	A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy	Completed	NCT01638000	Phase 3	Mirabegron;Solifenacin succinate
12	A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults	Completed	NCT00258102	Phase 3	Levofloxacin
13	A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults	Completed	NCT00258089	Phase 3	Levofloxacin
14	Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial	Completed	NCT01530620	Phase 3	Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
15	Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome	Completed	NCT00239317	Phase 3	Tamusulosin
16	Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome	Completed	NCT00239265	Phase 3	Tamuslosin
17	The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction	Recruiting	NCT04972890	Phase 2, Phase 3
18	An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Enrolling by invitation	NCT04042402	Phase 3	DCR-PHXC
19	Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)	Not yet recruiting	NCT05620784	Phase 3	Furosemide
20	A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)	Terminated	NCT00384891	Phase 3	Bacillus Calmette-Guérin
21	A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)	Withdrawn	NCT02254915	Phase 3	Bacillus Calmette-Guérin
22	Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients	Completed	NCT02307487	Phase 2	120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
23	Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells	Completed	NCT02291432	Phase 1, Phase 2
24	Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention	Completed	NCT04555343	Phase 1, Phase 2	Tranexamic acid
25	A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Completed	NCT03081858	Phase 1, Phase 2	TSD-001
26	A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Completed	NCT03847909	Phase 2	DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
27	A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis	Completed	NCT01613586	Phase 2	ASP3652;Placebo
28	A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.	Completed	NCT01340027	Phase 2	Mirabegron;Solifenacin succinate;Placebo
29	Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.	Completed	NCT03562897	Phase 2
30	A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Terminated	NCT04387448	Phase 2	GFB-887;Placebo
31	A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome	Terminated	NCT01060254	Phase 2	Placebo;JNJ-42160443
32	A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy	Terminated	NCT02401542	Phase 1, Phase 2	Vofatamab;Docetaxel;Placebo
33	A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy	Terminated	NCT03123055	Phase 1, Phase 2	B-701;Pembrolizumab
34	An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases	Terminated	NCT04950114	Phase 2	GFB-887
35	Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy	Withdrawn	NCT02961114	Phase 1, Phase 2
36	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects	Completed	NCT02052713	Phase 1	Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
37	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects	Completed	NCT02058576	Phase 1	Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
38	Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients	Completed	NCT01232010	Phase 1	Mirodenafil
39	Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients	Completed	NCT01231997	Phase 1	Udenafil
40	Pilot Study of Mycophenolate Mofetil in Congenital Uropathies	Completed	NCT00193635	Phase 1	mycophenolate mofetil
41	Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study	Recruiting	NCT04731376	Phase 1	Testosterone Cypionate
42	Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions	Not yet recruiting	NCT03899298	Phase 1
43	A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral	Not yet recruiting	NCT03258658	Phase 1
44	Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora	Not yet recruiting	NCT03463239	Phase 1
45	A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma	Terminated	NCT02386111	Phase 1	Combination of varlilumab and sunitinib
46	A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer	Terminated	NCT02543645	Phase 1	Combination of Varlilumab and Atezolizumab
47	Influence of Diuresis Timing (F+0 Vs F-15) on 99m Tc DTPA Renography for the Diagnosis of Suspected Obstructive Uropathy in Adult Hydronephrotic Patients.	Unknown status	NCT04564469		Furosemide
48	Staged Ureteroscopy After Initial Urinary Drainage Versus Direct Ureteroscopy in the Treatment of Pediatric Obstructive Calcular Anuria	Unknown status	NCT02139059
49	Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis	Unknown status	NCT04594161
50	GreenLight (532nm) LASER (XPS) Enucleation vs. Thulium LASER Enucleation of Prostate for Treatment of Benign Prostatic Hyperplasia	Unknown status	NCT03305861

Search NIH Clinical Center for Urinary Tract Obstruction

Sources

Genetic Tests for Urinary Tract Obstruction

Sources

Anatomical Context for Urinary Tract Obstruction

Organs/tissues related to Urinary Tract Obstruction:

MalaCards : Prostate, Kidney, Brain, Bone Marrow, Cervix, Spinal Cord, Smooth Muscle

Sources

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 5360)

#	Title	Authors	PMID	Year
1	Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP. ⁵³ ⁶²	Meeks JJ...Smith ND	18342929	2008
2	[Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency]. ⁵³ ⁶²	Morgunov LIu...Pushkar' DIu	18254226	2007
3	New paradigms for advanced prostate cancer. ⁵³ ⁶²	Petrylak DP	17554403	2007
4	Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. ⁵³ ⁶²	Oefelein MG...Resnick MI	15017212	2004
5	Glial cell line derived neurotrophic factor is expressed by epithelia of human renal dysplasia. ⁵³ ⁶²	El-Ghoneimi A...Peuchmaur M	12441997	2002
6	[Urinary enzyme excretion in childhood uropathy]. ⁵³ ⁶²	Schaffer P...Szabo A	12434629	2002
7	[Urinary excretion of Tamm-Horsfall protein, albumin and beta-2 microglobulin in children with recurrent urinary tract infection]. ⁵³ ⁶²	Wolska-Duda I...Kokot F	11579828	2001
8	[Screening for early detection of prostate cancer (first experience in Israel)]. ⁵³ ⁶²	Neheman A...Stein A	11242898	2001
9	Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. ⁵³ ⁶²	Borer JG...Freeman MR	10576204	1999
10	Clinical pharmacokinetics and pharmacodynamics of finasteride. ⁵³ ⁶²	Steiner JF	8846625	1996
11	Tamm-Horsfall protein: are serum levels a marker for urinary tract obstruction? ⁵³ ⁶²	Johnstone LM...Powell HR	7696106	1994
12	[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. ⁵³ ⁶²	Konda R...Ikeda S	1282579	1992
13	Atypical presentation of focal xanthogranulomatous pyelonephritis. ⁶²	Dhingra K...Osher M	36439935	2023
14	Intense 68 Ga-Pentixafor Activity in Idiopathic Retroperitoneal Fibrosis. ⁶²	Shu Q...Cai L	36026598	2022
15	Palliative urinary diversion in patients with malignant ureteric obstruction due to gynaecological cancer. ⁶²	Perri T...Korach J	31018967	2022
16	Severe Bilateral Hydroureteronephrosis Due to Chronic Obstructive Uropathy. ⁶²	Merhi B	36413454	2022
17	Fetal therapy of LUTO (lower urinary tract obstruction) - a follow-up observational study. ⁶²	Keil C...Weber S	34652254	2022
18	Xanthogranulomatous Pyelonephritis - A Diagnostic and Therapeutic Dilemma. ⁶²	Jang TL...Polenakovik HM	36473546	2022
19	Obstetric outcomes after fetal intervention - a single-center descriptive review. ⁶²	Narang K...Ruano R	36411675	2022
20	A case study of pyelolymphatic backflow demonstrated on CT. ⁶²	Khoo VM...Choo YS	36189162	2022
21	Current material engineering strategies to prevent catheter encrustation in urinary tracts. ⁶²	Yao Q...Chen B	36118951	2022
22	A Rare Co-association of Autoimmune Thyroiditis and Idiopathic Retroperitoneal Fibrosis. ⁶²	Adhikari R...Pattan V	36465222	2022
23	Complex vesical diverticulum, an unusual cause of obstructive uropathy. ⁶²	Zubenko Stepanova O...Corbaton Gomollon D	36062205	2022
24	Prenatal Detection of Vesico-Allantoic Cyst: Ultrasound and Autopsy Findings. ⁶²	Bonasoni MP...Aguzzoli L	36369825	2022
25	Pediatric urolithiasis: what can pediatricians expect from radiologists? ⁶²	Bernardor J...Cabet S	36329164	2022
26	Duplex renal collecting system presenting with hydroureteronephrosis following pelvic organ prolapse and sacrocolpopexy in an adult female. ⁶²	Shu TD...Ericson K	36033162	2022
27	Fetal Megacystis in the first trimester: Comparing management and outcomes between longitudinal bladder length groups. ⁶²	Ormonde M...Martins AT	36372362	2022
28	Prenatally Diagnosed Posterior Urethral Valves: Ethical Dilemmas of Fetal Intervention. ⁶²	Meier KM...Vemulakonda V	35680050	2022
29	Prostate primary intravascular large B-cell lymphoma: A case report. ⁶²	Gu L...Zhao Y	36386016	2022
30	The Effects of TRPC6 Knockout in Animal Models of Kidney Disease. ⁶²	Dryer SE...Kim EY	36421724	2022
31	Preputial urethrostomy with preservation of the local anatomy in 4 dogs. ⁶²	Giansetto T...Claeys S	36069396	2022
32	Non dilated obstructive uropathy secondary to tur-syndrome in patient with solitary kidney. ⁶²	Agostini E...Galosi A	36267342	2022
33	The Case \| An 80-year-old man with obstructive uropathy. ⁶²	Saint-Jacques C...Letavernier E	36272748	2022
34	Interventions for obstructive uropathy in advanced prostate cancer: a population-based study. ⁶²	Nathan A...Green JSA	35485254	2022
35	Identifying Common Molecular Mechanisms in Experimental and Human Acute Kidney Injury. ⁶²	Gerhardt LMS...McMahon AP	36402654	2022
36	Verapamil inhibited the development of ureteral stricture by blocking CaMK II-mediated STAT3 and Smad3/JunD pathways. ⁶²	Qing Z...Zeng M	35922702	2022
37	Selective angioembolization as a management strategy for angiomyolipoma causing urinary tract obstruction. ⁶²	Zagade T...Morley C	36199836	2022
38	Clues for the early loss of renal function in congenital hydronephrosis: Analysis of renal pelvis collagen ratio, diuresis renography and upper urinary tract morphology. ⁶²	Ulusoy O...Mirac Akgur F	36464563	2022
39	Effect of Endovascular Treatment on Urinary Obstruction Caused by Iliac Artery Aneurysm: A Case Series and Review of the Literature. ⁶²	Zhou Y...Liu B	35926787	2022
40	CT features of malignant tubular genital tract tumors in seven goats. ⁶²	Collins-Webb AG...Stieger-Vanegas SM	36383072	2022
41	Lower urinary tract obstruction caused by fibroepithelial polyp in a newborn boy. ⁶²	Jorgensen PH...Thorup JM	36016721	2022
42	Abdominal Evisceration: A Rare Complication of In Utero Vesicoamniotic Shunting. ⁶²	Galvez C...Gosalbez R	35623499	2022
43	Bilateral Renal Artery Thrombosis: A Case of Successful Kidney Recovery After Prolonged Anuria. ⁶²	Lemos Mendes MF...Marques S	36381786	2022
44	Congenital anterior urethral valves and diverticula. ⁶²	Rawat J...Singh S	36376124	2022
45	The importance of CT Urography in early diagnosis of anatomical variations in urogenital tract: case presentation. ⁶²	Dervishi B...Gafurri Z	36039085	2022
46	Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. ⁶²	Kanbay M...Perazella MA	36282399	2022
47	Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. ⁶²	Chazal T...Vaglio A	36374823	2022
48	Stone disease in low- and middle-income countries: could augmented reality have a role in its management? ⁶²	Watson G...Scotland KB	35993671	2022
49	Multiple pyonephrotic compartments with different microorganisms and an infected "calcium milk" in a patient with bilateral obstructive uropathy: A challenging case. ⁶²	Buchholz N...Haghpanah A	36126458	2022
50	Acute and Late Adverse Effects of Prostate-Only or Pelvic Stereotactic Radiation Therapy in Prostate Cancer: A Comparative Study. ⁶²	Murthy V...Phurailatpam R	35724773	2022

Sources

Genes for Urinary Tract Obstruction

Genes related to Urinary Tract Obstruction (0 elite genes):

(show all 46)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BNC2	Basonuclin 2	Protein Coding	20.27	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
2	UMOD	Uromodulin	Protein Coding	16.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7696106 11579828
3	HBEGF	Heparin Binding EGF Like Growth Factor	Protein Coding	14.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10576204
4	ALB	Albumin	Protein Coding	14.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	KLK3	Kallikrein Related Peptidase 3	Protein Coding	12.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15017212 17554403 18342929 (more) 11242898 18254226
6	NAGLU	N-Acetyl-Alpha-Glucosaminidase	Protein Coding	11.77	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12434629 1282579
7	B2M	Beta-2-Microglobulin	Protein Coding	11.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1282579
8	MIR192	MicroRNA 192	RNA Gene	8.44	DISEASES inferred ¹⁴ ¹⁴
9	MIR199A1	MicroRNA 199a-1	RNA Gene	8.29	DISEASES inferred ¹⁴ ¹⁴
10	FN1	Fibronectin 1	Protein Coding	7.75	DISEASES inferred ¹⁴
11	REN	Renin	Protein Coding	7.6	DISEASES inferred ¹⁴
12	AQP2	Aquaporin 2	Protein Coding	7.5	DISEASES inferred ¹⁴
13	GDNF	Glial Cell Derived Neurotrophic Factor	Protein Coding	7.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12441997
14	SMAD3	SMAD Family Member 3	Protein Coding	7.46	DISEASES inferred ¹⁴
15	HAVCR1	Hepatitis A Virus Cellular Receptor 1	Protein Coding	7.32	DISEASES inferred ¹⁴
16	SMAD2	SMAD Family Member 2	Protein Coding	7.3	DISEASES inferred ¹⁴
17	CCN2	Cellular Communication Network Factor 2	Protein Coding	7.24	DISEASES inferred ¹⁴
18	LCN2	Lipocalin 2	Protein Coding	7.04	DISEASES inferred ¹⁴
19	CRP	C-Reactive Protein	Protein Coding	6.96	DISEASES inferred ¹⁴
20	CDH1	Cadherin 1	Protein Coding	6.9	DISEASES inferred ¹⁴
21	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	6.9	DISEASES inferred ¹⁴
22	MIR142	MicroRNA 142	RNA Gene	6.86	DISEASES inferred ¹⁴ ¹⁴
23	ACE	Angiotensin I Converting Enzyme	Protein Coding	6.83	DISEASES inferred ¹⁴
24	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	6.83	DISEASES inferred ¹⁴
25	SMAD7	SMAD Family Member 7	Protein Coding	6.74	DISEASES inferred ¹⁴
26	MIR299	MicroRNA 299	RNA Gene	6.73	DISEASES inferred ¹⁴ ¹⁴
27	BMP7	Bone Morphogenetic Protein 7	Protein Coding	6.71	DISEASES inferred ¹⁴
28	UPK3A	Uroplakin 3A	Protein Coding	6.69	DISEASES inferred ¹⁴
29	PAX2	Paired Box 2	Protein Coding	6.65	DISEASES inferred ¹⁴
30	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.6	DISEASES inferred ¹⁴ ¹⁴
31	KL	Klotho	Protein Coding	6.55	DISEASES inferred ¹⁴
32	IL1B	Interleukin 1 Beta	Protein Coding	6.54	DISEASES inferred ¹⁴
33	NPHS1	NPHS1 Adhesion Molecule, Nephrin	Protein Coding	6.54	DISEASES inferred ¹⁴
34	SERPINE1	Serpin Family E Member 1	Protein Coding	6.49	DISEASES inferred ¹⁴
35	IL6	Interleukin 6	Protein Coding	6.48	DISEASES inferred ¹⁴
36	CST3	Cystatin C	Protein Coding	6.46	DISEASES inferred ¹⁴
37	TNF	Tumor Necrosis Factor	Protein Coding	6.45	DISEASES inferred ¹⁴
38	KRT7	Keratin 7	Protein Coding	6.31	DISEASES inferred ¹⁴
39	AQP1	Aquaporin 1 (Colton Blood Group)	Protein Coding	6.28	DISEASES inferred ¹⁴
40	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.26	DISEASES inferred ¹⁴
41	S100A4	S100 Calcium Binding Protein A4	Protein Coding	6.25	DISEASES inferred ¹⁴
42	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	6.23	DISEASES inferred ¹⁴
43	CTNNB1	Catenin Beta 1	Protein Coding	6.22	DISEASES inferred ¹⁴
44	FOXD1	Forkhead Box D1	Protein Coding	6.2	DISEASES inferred ¹⁴
45	CD68	CD68 Molecule	Protein Coding	6.19	DISEASES inferred ¹⁴
46	AVPR2	Arginine Vasopressin Receptor 2	Protein Coding	6.19	DISEASES inferred ¹⁴

Sources

Variations for Urinary Tract Obstruction

Sources

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Sources

Pathways for Urinary Tract Obstruction

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	11.83	SMAD3 SMAD2 FN1 CDH1
2	Cell adhesion_ECM remodeling ²²	11.39	KLK3 HBEGF FN1
3	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.3	SMAD3 SMAD2 CCN2
4	TGF-beta receptor signaling ⁶¹	11.24	SMAD3 SMAD2 CCN2
5	CCL18 signaling pathway ⁷⁴	11.24	SMAD3 SMAD2 FN1 CDH1
6	Envelope proteins and their potential roles in EDMD physiopathology ⁷⁴	10.99	SMAD3 SMAD2 CCN2
7	Hypothesized pathways in pathogenesis of cardiovascular disease ⁷⁴	10.73	SMAD3 SMAD2 CCN2
8	Regulation of cytoplasmic and nuclear SMAD2/3 signaling ⁶¹	10.59	SMAD3 SMAD2
9	SMAD2/3 MH2 Domain Mutants in Cancer ⁶⁶ Show member pathways Loss of Function of SMAD4 in Cancer ⁶⁶ SMAD4 MH2 Domain Mutants in Cancer ⁶⁶	10.41	SMAD3 SMAD2
10	TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition ⁷⁴	9.95	SMAD3 SMAD2 FN1

Sources

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.02	ALB B2M CCN2 CDH1 CRP FN1
2	extracellular space	GO:0005615	9.7	UMOD REN MIR199A1 MIR192 LCN2 KLK3
3	SMAD protein complex	GO:0071141	9.46	SMAD3 SMAD2

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	SMAD protein complex assembly	GO:0007183	9.56	SMAD3 SMAD2
2	ureteric bud development	GO:0001657	9.55	SMAD3 SMAD2 GDNF
3	regulation of binding	GO:0051098	9.26	SMAD3 SMAD2
4	paraxial mesoderm morphogenesis	GO:0048340	8.92	SMAD3 SMAD2